Radioactive antibody targets rare childhood cancer

NCT ID NCT04022213

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination treatment for desmoplastic small round cell tumor (DSRCT), a rare cancer that often spreads in the abdomen. Participants receive a single dose of a radioactive antibody called 131I-omburtamab directly into the abdomen, followed by targeted radiation to the whole abdomen. The goal is to see if this approach can delay or prevent the cancer from coming back after surgery and chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive antibody called 131I-omburtamab given through a catheter into the abdomen, plus external beam radiation
What this could lead to
If it works, this combination could help prevent or delay the return of this rare cancer after surgery and chemotherapy.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply widely. The treatment involves radiation and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.